Home / Health / Paradigm Health & FDA Speed Up Clinical Trials
Paradigm Health & FDA Speed Up Clinical Trials
8 May
Summary
- Paradigm Health's AI platform matches patients to clinical trials via EHRs.
- FDA partners with Paradigm Health to expedite trial review processes.
- This collaboration aims to reduce drug development costs and timelines.
Paradigm Health has partnered with the FDA to streamline clinical trial execution and regulatory review. This groundbreaking collaboration utilizes an AI-powered platform that extracts data directly from Electronic Health Records (EHRs) to identify patients for clinical trials. The system evaluates FDA-defined endpoints in real-time, transmitting only essential safety and efficacy signals to pharmaceutical sponsors and the agency.
This innovative approach, engineered to minimize manual data entry and unnecessary data transfers, seeks to reduce the substantial costs and lengthy timelines associated with drug development. Early collaborations are already underway with major pharmaceutical companies like Amgen and AstraZeneca, with trials progressing at leading medical centers.
The FDA's accelerated engagement, driven by leadership's recognition of current system inefficiencies, signifies a shift towards leveraging technology and AI. This initiative addresses challenges such as low patient recruitment rates and high drug development costs, with the ultimate goal of increasing patient access to new medications more efficiently.
